16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

• Full Name:	Tae Min Kim
• Current Position & Affiliation:	Professor, Seoul National University Hospital
• Country:	Republic of Korea

• Educational Background:

2023

PhD.	2012	Seoul National University College of Medicine, Seoul, Korea
M.D.	2000	Seoul National University College of Medicine, Seoul, Korea

• Professional Experience:

Since 2018	Professor, Department of Internal Medicine, Seoul National University Hospital
2013-2018	Associate Professor, Department of Internal Medicine, Seoul National University
	Hospital
2009-2013	Assistant Professor, Department of Internal Medicine, Seoul National University
	Hospital

• Professional Organizations:

Seoul National University Hospital, Seoul National University College of Medicine, Seoul National University Cancer Research Institute

• Main Scientific Publications:

Lee JK, <u>Kim TM</u>, Ju YS et al. Clonal History and Genetic Predictors of Transformation into Small Cell Carcinomas from Lung Adenocarcinomas. J Clin Oncol 2017; 35:3065-74

Gambacorti-Passerini C, <u>Kim TM</u> et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol 2018;93:607-14

Lee Y, <u>Kim TM</u>, el al. Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. J Thorac Oncol 2019;14:1556-66

Park S, <u>Kim TM</u>, et al. Combined blockade of polo-like kinase and pan-RAF is effective against NRASmutant non-small cell lung cancer cells. Cancer Lett 2020;495:135-44

Park HR, <u>Kim TM</u>, et al. Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR T790M-mutant non-small cell lung cancer. J Thorac Oncol 2021;16:1859-71